Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Parke-Davis
Doses are escalated based on safety assessments: As soon as a dose meets the criteria for "tolerated" or "not tolerated", doses are escalated or terminated, respectively. All patients are treated for 2 weeks, with follow-up visits scheduled 1 week and 1 month post-treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
Serological evidence of late-stage HIV-1 infection (ELISA and Western Blot).
CD4 T cell count less than or equal to 200 mm3.
HIV-1 RNA greater than or equal to 5,000 copies/mL.
You may not be if
Prior Medication:
Excluded:
Anti-HIV treatment within 8 weeks prior to entry.
Systemic steroids within 4 weeks prior to entry.
Prior Treatment:
Excluded:
Treatment with anticancer agents within 4 weeks prior to study.
Clareo Health | A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients
